While asthma control is defined as the extent to which the various manifestations of asthma are reduced by treatment, current guidelines of asthma recommend assessment of asthma control without consideration of airway inflammation. Our aim was to investigate the relationships between fractional exhaled nitric oxide (FeNO), a reliable marker of airway inflammation, and levels of asthma controls in patients treated with inhaled corticosteroid (ICS).
We enrolled 71 adult patients with asthma, who had been treated with ICS more than 4 months. Asthma control was assessed by the physician based on the Global Initiative for Asthma guidelines, and by the patients and by using Asthma Control Test (ACT). Statistical analyses were performed to analyze the relationships between FeNO and measures of asthma control and clinical indices for asthma manifestations.
There was no significant difference in FeNO levels between 3 groups according to levels of asthma control (controlled, partly controlled and uncontrolled) determined by the physician ( P = 0.81) and by the patients ( P = 0.81). In addition, FeNO values were not correlated with the ACT scores ( r = 0.031, P = 0.807), while FeNO showed peripheral blood eosinophil counts ( P < 0.001).